🔗 Share this article

While America undertakes historic adjustments to its vaccine schedules, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 vaccines during the pandemic and has zeroed in on alleged deaths following Covid immunization in her brief position at the FDA.

Proposed Changes to Pediatric Vaccine Schedule

Agency leaders planned to announce radical changes to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US at odds with a large portion of the international standard with no evidence for benefit. The planned update has been pushed back until the new year.

Instead of Vinay Prasad, Høeg is scheduled to speak at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the center this year.

A Shift at the Agency

This interim role may indicate a strengthened alliance between the drug and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a greater focus upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting certain childhood vaccine recommendations in the US in order to be more like the Danish model, a country with comprehensive healthcare and a number of inhabitants approximately the population of the state of Wisconsin.

In her initial statements, she has kept her attention on immunizations – traditionally the domain of Dr. Prasad, director of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Expertise

Dr. Høeg has no obvious track record in pharmaceutical research, regulation or administrative roles, which has been typical for past leaders of the CBER. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since March.

“It seems she lacks to have the necessary background” for running the CDER, stated Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a major agency. She has no expertise in industry regulation.”

Former heads of CBER would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who ran the center have had.”

The drug center has an immense portfolio at the agency, she pointed out.

“The public just focuses on the new drug program, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and so forth, and every single one must be managed,” she noted. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant administrative aspect to the job, which manages in excess of 5,000 staff members. “It is a huge leadership role, if you do it right,” she added.

Agency Reaction and Controversial Policies

When asked about questions about Dr. Høeg's credentials and whether this appointment indicates increased cooperation among regulatory chiefs on vaccines, a representative responded that the “inquiries rely on inaccurate presumptions”.

“Her resume matches the responsibilities of her position,” the official explained, citing the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's recently launched priority voucher program, a controversial rapid drug-approval program that allegedly concerned her preceding directors. “How are these medications being picked for this expedited pathway? Who is making the choices?” Howard asked. “There’s a lot of secrecy happening at the FDA right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards more relaxed oversight of pharmaceuticals, aside from shots.”

Documented History on Vaccines

With vaccines, Høeg has a more established, if concerning, history, Howard observe. She authored a research paper using unverified public submissions to assess the rate of heart inflammation following Covid immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership featured changing guidelines for recently developed shots and ending “unnecessary” immunizations, she remarked post-election on a online show. At the FDA, Høeg has allegedly proposed preventing teenage boys from getting COVID-19 vaccinations.

“She is an thorough ideologue who starts off with her beliefs and works backwards to accommodate the evidence in a very deceptive, dishonest fashion,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|